A claims-based study of nearly 4,000 Mississippi Medicaid members found that adherence to GLP-1 weight-loss drugs falls sharply within months, with the steepest declines linked to younger age, Black race, and early shortage initiation. The findings add to mounting evidence that real-world barriers—coverage, availability, and persistence—may limit outcomes even when drugs are clinically effective.